The investment bank expects new clinical data and the expiry of patents for existing weight loss drugs to unleash new opportunities.
from International: Top News And Analysis https://ift.tt/SPuYcN7
via IFTTT
Sunday, January 21, 2024
Missed the Novo and Lilly rally? These 4 under-the-radar anti-obesity drug stocks could soar, Berenberg says – giving one 44% upside
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment